Maurer U, Härle M, Jungius K P
Institut für Klinische Radiologie, Klinikum der Stadt Mannheim.
Strahlenther Onkol. 1996 May;172(5):257-9.
A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung. She died after the 2nd day of the first course on fatal myocardial infarction. The histological evaluation of the heart revealed no severe chronic fibrosis. In our opinion the myocardial infarction was partly 5-fluorouracil-related in this case.
Published case reports on this theme were reviewed and discussed.
The review of the literature showed a 5-FU associated cardiotoxicity in 98 cases. Most of the patients were without evidence of pre-existing myocardial disorders. The discussion about the reasons of the 5-FU-associated cardiotoxicity is still going on. Cardiotoxicity will rise up in 1.1% to 4.5% of the patients treated with 5-FU. Patients with a history of cardiac disease were at significantly increased risk for 5-FU-induced cardiotoxicity.
In high-risk-patients 5-FU should not be given without electrocardiographic monitoring. The continuous infusion is better than a bolus treatment.
一名53岁女性患者因肺癌接受了5-氟尿嘧啶(5-FU)联合放化疗。她在第一个疗程的第2天后死于致命性心肌梗死。心脏的组织学评估显示无严重慢性纤维化。我们认为在该病例中,心肌梗死部分与5-氟尿嘧啶有关。
对已发表的关于该主题的病例报告进行了回顾和讨论。
文献回顾显示98例患者存在5-FU相关的心脏毒性。大多数患者无既往心肌疾病证据。关于5-FU相关心脏毒性原因的讨论仍在进行。接受5-FU治疗的患者中,心脏毒性发生率为1.1%至4.5%。有心脏病史的患者发生5-FU诱导心脏毒性的风险显著增加。
在高危患者中,若无心电图监测,不应给予5-FU。持续输注优于大剂量推注治疗。